ArticleTechnology in cancer research & treatment
An Investigation into Planned Dose Preservation of Biology-guided Radiotherapy Under Various Radiopharmaceutical Uptake Conditions.
Article in Technology in cancer research & treatment. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
IntroductionPositron emission tomography-based biology-guided radiotherapy is an advanced radiation therapy technique that utilizes real-time imaging data from radiopharmaceuticals to deliver a tracked dose to a targeted area. The uptake of positron emission tomography radiopharmaceuticals in the same patient can vary due to changes in physiological condition and response to treatment. Thus, the robustness of the therapeutic approach under various uptake conditions is a property that needs to be understood.MethodsAn 18F-fluorodeoxyglucose fillable cylindrical phantom, which contained a spherical target measuring 22 mm in diameter and a c-shaped organ-at-risk, was placed inside the ArcCHECK device. Two treatment plans with identical constraints were developed, each based on unique planning positron emission tomography images, using the RefleXion X1 system. Plan 1 was based on a planning image with a target-to-background ratio of 8:1 while plan 2 was based on a planning image with a target-to-background ratio of 4:1. All pre-treatment go-no-go thresholds were disabled to allow all fractions to proceed to treatment regardless of PET characteristics. Twenty-five fractions of plan 1 were delivered in groups of five consecutive fractions, using phantoms prepared with different target-to-background ratios ranging from 10:1 to 2:1. Five fractions of plan 2 were delivered based on a phantom prepared with a similar target-to-background ratio as the plan. Each treatment fraction was characterized by its target activity concentration, normalized target signal, and effective target-to-background ratio. Treatment accuracy was evaluated using the 3%/2mm absolute gamma criteria.ResultsFor plan 1 and plan 2, 91.7% and 40% of deliveries exceeded a 90% 3%/2mm absolute gamma threshold, respectively. Of these deliveries which would be clinically allowed by the machine, 100% exceeded the 90% 3%/2mm.ConclusionFor deliveries meeting the minimum activity concentration and normalized target signal requirements for target-to-background ratios of 6:1 to 10:1, positron emission tomography-based biology-guided radiotherapy demonstrated robust, and accurate treatment results for static targets. For target-to-background ratios of 2:1 and 4:1, which are not clinically deliverable, the treatment gamma results demonstrated signal-limited instability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.